127 related articles for article (PubMed ID: 17585892)
1. Human kallikrein 10 ELISA development and validation in breast cancer sera.
Ewan King L; Li X; Cheikh Saad Bouh K; Pedneault M; Chu CW
Clin Biochem; 2007 Sep; 40(13-14):1057-62. PubMed ID: 17585892
[TBL] [Abstract][Full Text] [Related]
2. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815
[TBL] [Abstract][Full Text] [Related]
4. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Yousef GM; Polymeris ME; Grass L; Soosaipillai A; Chan PC; Scorilas A; Borgoño C; Harbeck N; Schmalfeldt B; Dorn J; Schmitt M; Diamandis EP
Cancer Res; 2003 Jul; 63(14):3958-65. PubMed ID: 12873991
[TBL] [Abstract][Full Text] [Related]
6. Human kallikrein 10, a predictive marker for breast cancer.
Zhang Y; Bhat I; Zeng M; Jayal G; Wazer DE; Band H; Band V
Biol Chem; 2006 Jun; 387(6):715-21. PubMed ID: 16800732
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
Santin AD; Diamandis EP; Bellone S; Marizzoni M; Bandiera E; Palmieri M; Papasakelariou C; Katsaros D; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2006 May; 194(5):1296-302. PubMed ID: 16647913
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay of total inhibin: direct determination based on inhibin alpha subunit-specific monoclonal antibodies.
Khosravi J; Krishna RG; Khaja N; Bodani U; Diamandi A
Clin Biochem; 2004 May; 37(5):370-6. PubMed ID: 15087252
[TBL] [Abstract][Full Text] [Related]
9. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues.
Luo LY; Grass L; Howarth DJ; Thibault P; Ong H; Diamandis EP
Clin Chem; 2001 Feb; 47(2):237-46. PubMed ID: 11159772
[TBL] [Abstract][Full Text] [Related]
10. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma.
Diamandis EP; Okui A; Mitsui S; Luo LY; Soosaipillai A; Grass L; Nakamura T; Howarth DJ; Yamaguchi N
Cancer Res; 2002 Jan; 62(1):295-300. PubMed ID: 11782391
[TBL] [Abstract][Full Text] [Related]
11. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients.
Gauchez AS; Ravanel N; Villemain D; Brand FX; Pasquier D; Payan R; Mousseau M
Anticancer Res; 2008; 28(5B):3067-73. PubMed ID: 19031958
[TBL] [Abstract][Full Text] [Related]
13. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.
Paliouras M; Diamandis EP
Breast Cancer Res Treat; 2007 Mar; 102(1):7-18. PubMed ID: 16897430
[TBL] [Abstract][Full Text] [Related]
14. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
[TBL] [Abstract][Full Text] [Related]
15. Human tissue kallikrein gene family: applications in cancer.
Obiezu CV; Diamandis EP
Cancer Lett; 2005 Jun; 224(1):1-22. PubMed ID: 15911097
[TBL] [Abstract][Full Text] [Related]
16. A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid synthase.
Wang YY; Kuhajda FP; Cheng P; Chee WY; Li T; Helzlsouer KJ; Sokoll LJ; Chan DW
J Immunoassay Immunochem; 2002; 23(3):279-92. PubMed ID: 12227415
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemistry study of tissue bcl-2 expression and its serum levels in breast cancer patients.
Alireza A; Raheleh S; Abbass R; Mojgan M; Mohamadreza M; Gholamreza M; Shadi B
Ann N Y Acad Sci; 2008 Sep; 1138():114-20. PubMed ID: 18837891
[TBL] [Abstract][Full Text] [Related]
18. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
19. Human kallikrein 10: a novel tumor marker for ovarian carcinoma?
Luo LY; Bunting P; Scorilas A; Diamandis EP
Clin Chim Acta; 2001 Apr; 306(1-2):111-8. PubMed ID: 11282101
[TBL] [Abstract][Full Text] [Related]
20. Identification of mammaglobin as a novel serum marker for breast cancer.
Bernstein JL; Godbold JH; Raptis G; Watson MA; Levinson B; Aaronson SA; Fleming TP
Clin Cancer Res; 2005 Sep; 11(18):6528-35. PubMed ID: 16166429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
